ketoconazole has been researched along with icotinib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Hu, P; Jiang, J; Liu, D; Zhao, Q; Zheng, X | 1 |
| Che, J; Li, H; Li, Z; Lu, C; Luo, H; Wang, J; Yang, H; Yue, S; Zhang, T; Zhang, Y; Zhu, M; Zhuang, X | 1 |
2 other study(ies) available for ketoconazole and icotinib
| Article | Year |
|---|---|
Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug-drug interaction between icotinib and CYP3A4 inhibitors/inducers using physiologically based pharmacokinetic modeling.
Topics: Antineoplastic Agents; Area Under Curve; Computer Simulation; Crown Ethers; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Ketoconazole; Male; Microsomes, Liver; Models, Biological; Quinazolines; Rifampin | 2015 |
Allosteric activation of midazolam CYP3A5 hydroxylase activity by icotinib - Enhancement by ketoconazole.
Topics: Allosteric Regulation; Animals; Antineoplastic Agents; Crown Ethers; Cytochrome P-450 CYP3A; Dogs; Dose-Response Relationship, Drug; Drug Interactions; Haplorhini; Humans; In Vitro Techniques; Ketoconazole; Mice; Microsomes, Liver; Midazolam; Quinazolines; Rats; Species Specificity; Substrate Specificity | 2016 |